• Barry Hafkin

    • Dr. Hafkin joined MicuRx as our Chief Medical Officer in September 2015, and now he is a special consultant.
    • Dr. Hafkin is an experienced physician specializing in adult infectious diseases and a seasoned executive with experience at both large pharma and small biotech companies.
    • Prior to MicuRx, Dr. Hafkin served in executive roles at Nobelex, Affinium Pharmaceuticals, Cumbre Pharmaceuticals, and Advancis Pharmaceuticals, where he was responsible for all aspects of pharmaceutical development, registration, and marketing support. Previously, he served as senior director involved in the development of linezolid at Pharmacia which was acquired by Pfizer in 2003.
    • Prior to Pharmacia, Dr. Hafkin maintained an infectious disease and epidemiology practice. He also served as a principal investigator for the Epidemic Intelligence Service of the Centers for Disease Control. He received his M.D. from the University of Texas Medical School in San Antonio.